Review Article
MicroRNAs in Diabetic Kidney Disease

Rong Li,1,2,3 Arthur C. K. Chung,1,4 Xueqing Yu,5 and Hui Y. Lan1,4,6

1 Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong
2 Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong
3 Department of Nephrology, The First People’s Hospital of Yunnan Province, Yunnan, China
4 Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, China
5 Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
6 Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong

Correspondence should be addressed to Arthur C. K. Chung; chungack@cuhk.edu.hk

Received 4 July 2013; Accepted 22 December 2013; Published 14 January 2014

Copyright © 2014 Rong Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Rapid growth of diabetes and diabetic kidney disease exerts a great burden on society. Owing to the lack of effective treatments for diabetic kidney disease, treatment relies on drugs that either reduces its progression or involve renal replacement therapies, such as dialysis and kidney transplantation. It is urgent to search for biomarkers for early diagnosis and effective therapy. The discovery of microRNAs had lead to a new era of post-transcriptional regulators of gene expression. Studies from cells, experimental animal models and patients under diabetic conditions demonstrate that expression patterns of microRNAs are altered during the progression of diabetic kidney disease. Functional studies indicate that the ability of microRNAs to bind 3’ untranslated region of messenger RNA not only shows their capability to regulate expression of target genes, but also their therapeutic potential to diabetic kidney disease. The presence of microRNAs in plasma, serum, and urine has been shown to be possible biomarkers in diabetic kidney disease. Therefore, identification of the pathogenic role of microRNAs possesses an important clinical impact in terms of prevention and treatment of progression in diabetic kidney disease because it allows us to design novel and specific therapies and diagnostic tools for diabetic kidney disease.

1. Epidemiology and Diabetes

The prevalence of diabetes is rising worldwide and is expected to reach the devastating number of 439 million by the year 2030 from 285 million in 2010 [1]. This huge elevation is attributed to an escalating tendency towards sedentary lifestyle and westernized choice of diet, leading to obesity. Furthermore, the age of onset for the type 2 diabetic patients is showing a trend to begin in youths [2]. Diabetes is a significant public health concern as its rising incidence has greatly increased the cost of treating both diabetes and its numerous debilitating complications.

2. Diabetic Kidney Disease

Diabetic kidney disease is one of the diabetic microvascular complications. Type 1 and type 2 diabetes are distinct in etiology and pathogenesis. In spite of different morphological changes of renal injury in type 1 and type 2 diabetic patients [3], type 1 and type 2 diabetic patients have similar risks of renal injury in diseased kidney [4]. The characteristics of diabetic renal injury includes the effacement of podocyte foot processes, gradual mesangial cell (MC) proliferation and hypertrophy, excessive accumulation of extracellular matrix (ECM) proteins, mesangial expansion, and thickening of the glomerular basement membrane (GBM) [5]. These events eventually lead to nodular glomerulosclerosis (Kimmelstiel-Wilson lesions) [6]. Similar changes occur in the tubulointerstitial, such as tubular hypertrophy, thickening of the tubular basement membrane (TBM), and interstitial fibrosis [6].

The clinical manifestations of diabetic kidney disease are microalbuminuria (30–300 mg/day), followed by macroalbuminuria (>300 mg/day), gradual loss of renal function, and elevation of arterial blood pressure and terminated in renal failure for some patients. Current interventions of diabetic kidney disease including rigorous glycemic control...
and antihypertensive therapy and angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are the first-line drugs. ACEIs and ARBs have been shown to slow down the progression of kidney disease [7–11]. However, there is no effective therapy to halt the progression to the end-stage renal disease (ESRD) after the nephropathy has been established [12].

In addition, diabetic kidney disease is also associated with macrovascular diseases, such as cardiovascular disease. In USA, diabetic kidney disease accounts for almost 50% of all ESRD [6]. Dialysis or kidney transplantation is useful to control uraemia and other symptoms of renal failure in patients with ESRD. But the prognosis for patients with ESRD due to diabetes is not optimistic because less than 50% of patients survive beyond 5 years after diagnosis [13] and the five-year survival rates are similar to those among patients with metastasized gastrointestinal carcinoma [12]. Given the ever-increasing population with diagnosed diabetes and irreversible renal injury after onset of diabetic kidney disease, to develop effective therapy is an urgent need to combat diabetic kidney diseases.

3. MicroRNAs

MicroRNAs are short noncoding RNAs 22–25 nucleotides long. As an endogenous production transcript, microRNAs can bind to the 3’ untranslated region (3’UTR) of its target messenger RNA (mRNA) by imperfect complementary manner, leading to posttranscriptional gene silencing. As a result, microRNAs can inhibit gene expression via mRNA degradation, translation inhibition, or transcriptional inhibition [14, 15]. After the discovery of the first microRNA two decades ago, our knowledge of gene regulation and disease mechanisms has been renovated extensively. Nowadays, the critical role of microRNAs has been established in several cellular and biologic processes, such as proliferation, differentiation, and development, and in the regulation of genes relation to immune responses, cancer, and insulin secretion [16–19]. Because microRNAs are vital regulators of gene expression, aberrant of microRNAs are present in human diseases including cancer, hepatitis, and diabetes [17, 20–23]. There are also emerging reports about microRNAs in renal field. Several comprehensive reviews of microRNAs research on kidney development, function, and diseases have been previously published [24–39]. This review will focus on the current research progress of microRNAs in diabetic kidney disease.

4. MicroRNAs in the Pathogenesis of Diabetic Kidney Disease

The two cornerstones of progressive diabetic kidney disease are glomerulosclerosis and interstitial fibrosis. Injury of MCs and tubular epithelial cells (TECs) naturally contributed to fibrosis in diabetic kidney disease. Aberrant glucose metabolism results in accumulation of various byproducts such as advanced glycation end products (AGEs), elevation of reactive oxygen species (ROS) and activation of protein kinase C (PKC). All of these events induce TGF-β signaling to induce renal fibrosis. Thus, hyperglycemia as a trigger initiates the cascade of renal injury in diabetic kidney disease.

In the biosynthetic process of microRNAs, Dicer is involved in both microRNAs biogenesis and microRNAs-mediated gene silencing [40–43]. As podocytes in the glomerular basement membrane are critical in maintaining the glomerular filtration barrier, podocyte dysfunction will lead to glomerular pathologies as in diabetic nephropathy (DN) or other types of glomerulonephritis [44]. Studies from mice with podocyte-specific deletion of Dicer [45–47] demonstrate that the loss of microRNAs resulted from deletion of Dicer leads to proteinuria, podocyte injury, and renal fibrosis. These results suggest the critical role of microRNAs in the podocytes to maintain the normal renal functions. Today, emerging evidences indicate microRNAs as vital regulators of gene expression during diabetic kidney disease. MicroRNAs involved in diabetic kidney disease were listed in Tables 1 and 2.

4.1. miR-192

The first landmark report about the role of microRNA in diabetic kidney disease was performed by Kato et al. [48]. They show that miR-192 levels increase significantly in glomeruli isolated from streptozotocin-injected diabetic mice as well as diabetic db/db mice, in parallel with increased TGF-β1 and collagen Ia2 (Colla2) levels. Upregulation of renal miR-192 during diabetic kidney diseases is also found in db/db mice, type 2 diabetes rat, and whole blood samples of type 2 diabetes patients [49–52]. In addition, TGF-β1 induces miR-192 levels in both mouse MCs and isolated glomeruli from both type 1 and type 2 mouse models of diabetes [48, 52]. Other studies also show miR-192 upregulation in MCs and TECs after treatment with high glucose, AGE, and TGF-β1 [53–55]. These studies demonstrate that the elevation of renal miR-192 is highly correlated with diabetic condition.

Recent studies demonstrate several possible mechanisms of how miR-192 mediates renal fibrosis. Firstly, miR-192 targets the 3’untranslated region of its target mRNA by imperfect complementary manner. Because microRNAs are vital regulators of gene expression, aberrant of microRNAs are present in human diseases including cancer, hepatitis, and diabetes [17, 20–23]. There are also emerging reports about microRNAs in renal field. Several comprehensive reviews of microRNAs research on kidney development, function, and diseases have been previously published [24–39]. This review will focus on the current research progress of microRNAs in diabetic kidney disease.
Table 1: Summary of microRNAs in diabetic kidney disease (upregulation).

<table>
<thead>
<tr>
<th>microRNA</th>
<th>In vitro (cell type)</th>
<th>In vivo (animal mode)</th>
<th>Target</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-192</td>
<td>MCs (human, rat, and mouse)</td>
<td>STZ induced DN mice, DN in db/db mice</td>
<td>Sip-1</td>
<td>[48–50, 52–54]</td>
</tr>
<tr>
<td>miR-216a</td>
<td>Primary MCs (mouse)</td>
<td>STZ induced DN mice, DN in db/db mice</td>
<td>PTEN</td>
<td>[56]</td>
</tr>
<tr>
<td>miR-217</td>
<td>Primary MCs (mouse)</td>
<td>STZ induced DN mice, DN in db/db mice</td>
<td>Ybx1</td>
<td>[57]</td>
</tr>
<tr>
<td>miR-216a</td>
<td>MCs (mouse)</td>
<td>STZ induced DN mice, DN in db/db mice</td>
<td>Zeb1/2</td>
<td>[52, 90]</td>
</tr>
<tr>
<td>miR-215</td>
<td>MCs (human and rat) PTEs (mouse)</td>
<td>OVE26 type 1 diabetic mice (12 weeks of age)</td>
<td>CTNNBIP1</td>
<td>[50]</td>
</tr>
<tr>
<td>miR-21</td>
<td>Primary MCs (mouse) STZ induced DN mice, STZ induced DN in APOE knockout mice (10 weeks of age)</td>
<td>Zeb2</td>
<td>[61]</td>
<td></td>
</tr>
<tr>
<td>miR-200b/c</td>
<td>MCs (mouse)</td>
<td>PTEN</td>
<td>Soy6</td>
<td>[95]</td>
</tr>
<tr>
<td>miR-377</td>
<td>MCs (human and mouse) spontaneous [(NOD/Lt) mice] and STZ induced DN mice</td>
<td>PAK1 and MnSOD</td>
<td>[53]</td>
<td></td>
</tr>
</tbody>
</table>

PTE: proximal tubule epithelial cells; TEC: tubular epithelial cells; MC: mesangial cells; STZ: streptozotocin; DN: diabetic nephropathy.

Table 2: Summary of microRNAs in diabetic kidney disease (downregulation).

<table>
<thead>
<tr>
<th>microRNA</th>
<th>In vitro (cell type)</th>
<th>In vivo (animal mode)</th>
<th>Target</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-192</td>
<td>PTE human (HK-2 cells)</td>
<td>Patients with established DN</td>
<td>Zeb2</td>
<td>[60, 61]</td>
</tr>
<tr>
<td>miR-215</td>
<td>Primary MCs and PTECs (rat)</td>
<td>STZ induced DN in APOE knockout mice (10 weeks of age)</td>
<td>Zeb2</td>
<td>[61]</td>
</tr>
<tr>
<td>miR-21</td>
<td>Primary MCs (mouse)</td>
<td>db/db mice (8 weeks of age)</td>
<td>PTEN</td>
<td>[67]</td>
</tr>
<tr>
<td>miR-200a</td>
<td>TEC (rat)</td>
<td>STZ induced DN in apolipoprotein E knockout mice</td>
<td>TGF-β2</td>
<td>[88]</td>
</tr>
<tr>
<td>miR-29a</td>
<td>PTE human (HK-2 cells)</td>
<td>Col IVA1 and Col IVA2</td>
<td>Zeb2</td>
<td>[77]</td>
</tr>
<tr>
<td>miR-25</td>
<td>MCs (rat)</td>
<td>STZ induced DN rat</td>
<td>Nox4</td>
<td>[95]</td>
</tr>
<tr>
<td>miR-45i</td>
<td>Primary MCs (mouse) Renal microvascular</td>
<td>Early DN (db/db mice)</td>
<td>Ywhaz</td>
<td>[96]</td>
</tr>
<tr>
<td>miR-93</td>
<td>Endothelial cell Mouse podocytes</td>
<td>db/db mice</td>
<td>VEGF-A</td>
<td>[94]</td>
</tr>
</tbody>
</table>

PTE: proximal tubule epithelial cells; TEC: tubular epithelial cells; MC: mesangial cells; STZ: streptozotocin; DN: diabetic nephropathy.

In patients with established diabetic kidney disease, low expression of miR-192 is correlated with tubulointerstitial fibrosis and low estimated glomerular filtration rate (GFR) [60]. In HK-2 cells, a human proximal TEC line, TGF-β1 (10 ng/mL for 96 h) reduces the expression of miR-192 and zinc finger E-box binding homeobox 1 (Zeb1) accompanied by a reduction of E-cadherin and upregulation of zinc finger E-box binding homeobox 2 (Zeb2), PAI-1, and vimentin [60]. Wang et al. also reported that decreased expression of miR-192 and miR-215 by TGF-β1 (10 ng/mL for 72 h) in primary rat MCs and TEC, and in the renal cortex of apolipoprotein E knockout mice at 10 weeks of diabetes [61]. These observed differences in murine models may be due to the different models and time points that were used [56, 61]. Reduced miR-192 and miR-215, which target Zeb2, are involved in TGF-β/CTGF-mediated changes in E-cadherin expression, demonstrating that miR-192/215 may not affect fibrosis by directly altering the expression of fibrotic markers and ECM proteins [61]. The different findings in expression of miR-192 in human and animal models of diabetic kidney disease reveal the complexity of signaling mechanism during diabetic kidney injury.

4.2. miR-21. miR-21 is another profibrotic microRNA because results of in vitro studies show that miR-21
expression is upregulated in TECs and MCs after treatment with TGF-β1 or under diabetic condition [54, 62–65]. Elevation of miR-21 in renal cortices has been demonstrated in type 1 (OVE26) and type 2 (kk-ay and db/db) diabetic mouse models [63–66], although downregulation of miR-21 expression is reported during early DN in diabetic db/db mice [67]. Recently miR-21 expression has been found to be increased in kidney biopsies from diabetic patients compared to healthy controls [66]. In addition, the pro-fibrotic property of miR-21 is further confirmed by functional analyses as miR-21 positively regulates expression of ECM and α-SMA in TECs and MCs after treatment of TGF-β1 or under diabetic condition [54, 62–65]. Overexpression of miR-21 in kidney cells also promotes but knockdown of miR-21 reduces renal inflammation under diabetic condition [63].

The exact mechanism of how miR-21 participates in diabetic renal injury may be related to its putative target genes and the activation of TGF-β signaling during diabetic condition [68, 69]. miR-21 may activate the TGF-β canonical signaling by suppressing Smad7, an inhibitory Smad [63]. Furthermore, miR-21 may mediate the TGF-β noncanonical signaling by targeting Sprouty (SPRY) because SPRY is a potent inhibitor of Ras/MEK/ERK and then suppress TGF-β-dependent fibrogenic activities [70]. As phosphatase and tensin homolog (PTEN) is one of potential targets of miR-21 [71, 72], upregulation of Akt pathway may be another mechanism for miR-21 to participate in diabetic kidney injury. Suppression of PTEN by miR-21 is shown to induce phosphatidylinositol 3-kinases (PI3K) and Akt activity, and subsequently induces metalloproteinase-2 (MMP-2) expression [71]. The reciprocal regulation of PTEN levels and AKT1 substrate 1 (PRAS40), a negative regulator of Tor complex 1 (TORC1) activity by miR-21, is shown to mediate critical pathologic features of diabetic kidney disease [64]. During fibrosis, ECM turnover is controlled by both metalloproteinases and tissue inhibitors of metalloproteinases (TIMPs) activities. The findings of TIMP3 as a potential miR-21 target, demonstrate that miR-21 may mediate several pathways to promote renal injury during diabetic kidney diseases [66]. Further studies should be done to clarify how miR-21 regulates inflammation as renal inflammation plays a vital role in diabetic kidney disease [63].

4.3. miR-29. Unlike miR-192 and miR-21, miR-29 is an anti-fibrotic microRNA. Expression of miR-29 family (miR-29a, miR-29b, and miR-29c) maintains a high level in normal kidney, lung, and heart [73] and its expression is dramatically reduced in animal models and human samples of fibrotic diseases in heart, lung, and kidney [74–76]. In addition, treatment with TGF-β1 or under diabetic condition reduce the expression of the miR-29 family in cultured MCs, TECs, and podocytes and increases expression of ECM proteins [54, 74, 77, 78], indicating that miR-29 may play a protective role during renal injury.

Its protective role against fibrosis has been demonstrated in different disease models. In cell lines from heart, lung, and kidney with TGF-β treatment, overexpression of miR-29 suppresses but inhibition of miR-29 promotes expression of fibrotic markers [70, 74, 75, 78–81]. Gene delivery of miR-29b either before or after established obstructive nephropathy successfully blocks progressive renal fibrosis in a mouse model of unilateral ureteral obstruction nephropathy [74], providing a strong support of anti-fibrotic properties of miR-29. Results from heart, lung, and kidneys also demonstrate that the anti-fibrotic effects of miR-29 are mediated through its ability to suppress the ECM-related gene transcription because more than 20 different ECM-related genes have been validated as direct targets of miR-29 by reporter gene assays and some of them are induced by TGF-β signaling [75, 80, 82].

The anti-fibrotic properties of miR-29 are also true in diabetic condition that suppression of miR-29a increased the risk of excess collagen deposition [77]. In addition, miR-29a in HK-2 cells negatively regulates collagen IV (Col IV) expression and directly targets the 3′ UTRs of the collagen genes Col IV α1 and Col IV α2 [77]. On the other hand, miR-29c expression is increased in the diabetic kidneys from type 2 diabetic mouse model. Ectopic expression of miR-29c promotes the progression of diabetic kidney disease via targeting Sprouty homolog-1 and stimulation Rho kinase [49]. This difference may be due to the fact that different kidney disease models may have different expressions of miR-29 family. Thus, we speculate that each miR-29 family member may have distinct biological action on renal tissue remodeling.

4.4. miR-200. The well-established function of miR-200 family (miR-200a, miR-200b, miR-200c, miR-429, and miR-141) is to maintain epithelial differentiation and this ability is believed to be the mechanism for miR-200 family to suppress fibrosis [83–85]. These microRNAs are shown to be suppressed in cells that have undergone epithelial to mesenchymal transition (EMT) in response to TGF-β [84–87], suggesting that TGF-β regulates the expression of these microRNAs to promote EMT. It is generally believed that proximal TECs may undergo EMT to induce renal fibrosis [88]. However, this notion that EMT contributes to renal fibrosis has recently been challenged.

In renal TECs, treatment with TGF-β1 and TGF-β2 suppresses expression of the miR-200 family in a Smad signaling dependent manner [88, 89]. This reduction is further confirmed in a mouse model of diabetic kidney disease that reduction of renal miR-200a and miR-141 occurs in diabetic kidneys [88], suggesting that miR-200 family plays a protective role in diabetic kidney disease.

However, it is also found that amounts of miR-200b/c are elevated in glomeruli from type 1 (streptozotocin) and type 2 (db/db) diabetic mice and in mouse mesangial cells treated with TGF-β1 in vitro [52]. Recently, inducing miR-200b and miR-200c and their target FOG2, an inhibitor of phosphatidylinositol 3-kinase activation, is shown to be one of the mechanisms of how TGF-β activates Akt in glomerular mesangial cells [90]. The reduction of FOG2 expression is observed in the glomeruli of diabetic mice and TGF-β-treated mouse MC. It is unexpected that increase of miR-200b/c levels is detected in diabetic mouse glomeruli and TGF-β-treated MC [90]. Transfection with miR-200b/c mimics in MC considerably reduces FOG2 expression and
increases cell hypertrophy which is confirmed by FOG2 knockdown in MC. In addition, suppression of FOG2 by miR-200b/c also activates ERKs, which is through PI3K activation [90]. These new findings suggest a new mechanism for TGF-β-induced Akt activation through FOG2 suppression by miR-200b/c, which results in glomerular mesangial hypertrophy during DN. However, the differences of miR-200 expression in diabetic kidneys are possibly due to the differences in the origin of cell lines examined, the treatments performed, and the use of different animal models between studies.

4.5. MicroRNAs in Glomerular Permeability and Podocytes. Podocytes are epithelial cells of the visceral layer of a renal glomerulus and they play a critical role in maintaining glomerular permeselectivity, regulating the synthesis of ECM proteins in glomerular basement membrane (GBM) [5]. It is well accepted that loss of glomerular podocytes, accumulation of extracellular ECM in glomeruli, and hypertrophy and expansion in the glomerular mesangium are key events in the progression of DN [44], resulting in proteinuria and declining function.

Studies from two independent lines of Dicer KO mice generated for podocytes [45, 47] demonstrate that mutant mice developed proteinuria by three weeks after birth and progressed rapidly to end-stage kidney disease. Multiple abnormalities, including foot process effacement, irregular and split areas of the glomerular basement membrane, podocyte apoptosis and depletion, mesangial expansion, capillary dilation, and glomerulosclerosis, were observed in glomeruli of mutant mice [47], demonstrating that proper processing of microRNAs in podocytes is required.

Recently, specific deletion of Dicer in mouse podocyte reveals an enrichment of predicted miR-30 target genes among the upregulated genes [91]. miR-30s are shown to be expressed abundantly in glomerular podocytes in mice and TGF-β suppresses expression of miR-30s in podocytes [91]. As TGF-β expression and TGF-β signaling activated during diabetic condition, downregulation of miR-30s in podocyte may be responsible of the TGF-β-induced podocyte apoptosis.

Urinary podocyte excretion is observed in DN which is related to the reduced adhesive capacity during podocyte damage [92]. Recent studies demonstrate that miR-124 expression is related to adhesive capacity damage of podocyte [93]. During DN, renal miR-124 expression is upregulated in STZ-induced uninephrectomized diabetic rats and suppression of miR-124 ameliorates adhesive capacity of podocyte [93].

Comparative microRNA expression profile arrays identified miR-93 as one of the five microRNAs downregulated in glomeruli from db/db mice as well as in podocytes/microvascular endothelial cells exposed to a high glucose milieu [94]. The decrease in miR-93, targeting VEGF, may also be of relevance for increasing glomerular permeability of DN.

4.6. Other MicroRNAs. There are other microRNAs involved in pathogenesis of diabetic kidney disease and we list here the major findings of these microRNAs. Further studies on these microRNAs may shed more light on their roles in diabetic kidney disease.

MiR-25 serves as an endogenous silencer for the NADPH oxidase 4 (Nox4) gene in mesangial cells [95]. Downregulation of miR-25 by high glucose in MCs or in rat diabetic kidney results in the relief of Nox4 gene silencing and leads to increased Nox4 expression and ROS production [95], suggesting that miR-25 may play a role in protecting the kidney from oxidative stress.

MiR-215 may participate in Wnt/β-catenin signaling as miR-215 is dramatically upregulated under diabetic conditions both in vitro (MCs) and in vivo (db/db mice) [50] and miR-215 mediates TGF-β1-induced MC activation and fibronectin expression via a β-catenin dependent pathway [50].

MiR-451 protects mesangial hypertrophy as renal miR-451 is downregulated during early diabetic kidney disease in db/db mice by regulating p38 mitogen-activated protein kinases (MAPK) signaling by targeting of Ywhaz (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta) [96].

MiR-377 may be involved in fibronectin production and oxidative stress during diabetic kidney disease. Its expression is elevated in both MCs (human and mouse) and in kidney of spontaneous (NOD/Lt) and STZ-induced type 1 diabetes mouse model [53]. MiR-377 targets p21-activated kinase-1 (PAK1) and manganese superoxide dismutase (MnSOD), which indirectly leads to upregulation of fibronectin [53].

MiR-93 is one of signature microRNAs in hyperglycemic conditions [94]. This microRNA is primarily expressed in glomeruli and TECs. However, its expression is inhibited in cultured podocyte cells, renal microvascular endothelial cells, and glomeruli of diabetic mice [94]. In culture, elevated expression of miR-93 reduces vascular endothelial growth factor (VEGF) expression and VEGF is a predicted target of miR-93 [94]. As VEGF targets collagen IV and fibronectin, the repression of miR-93 during diabetic kidney disease may contribute to the production of collagen and fibronectin.

Overall, the aberrant expression of these microRNAs in pathogenesis elicits the critical role of microRNAs in diabetic kidney disease.

5. Regulatory Mechanisms of MicroRNA during DN

The exact mechanism of how diabetic condition regulates microRNA expression during kidney diseases is still ongoing. It is believed that TGF-β signaling is responsible to promote synthesis of microRNAs during diabetic condition [39]. It has been reported that TGF-β signaling enhances the processing of primary transcripts of some microRNAs into its mature form by the Drosha complex [97]. Smad3 physically interacts with Drosha to promote the processing of pri-miR-21 into mature miR-21.

Our laboratory also demonstrates that TGF-β/Smad3 signaling mediates the transcription of miR-21, miR-192, miR-433, and the miR-29 family during renal diseases [55, 62,
TGF-β inhibits miR-29 expression but stimulates miR-21 and miR-192 expression via the Smad3-dependent mechanism as demonstrated in MCs and TECs knocking down Smad2 or Smad3, or overexpressing Smad7, and in Smad2 or Smad3 KO mouse embryonic fibroblasts (MEF) [54, 55, 62, 74]. In addition, Smad3 physically interacts with Smad binding site (SBE) located in its promoters to regulate the expression of these microRNAs [55, 62, 74, 98]. The ability to regulate TGF-β/Smad3-mediated microRNAs via maintaining renal miR-29b but suppressing miR-192 and miR-21 is found to be one of the mechanism of how Smad7, an inhibitory Smad, protects kidneys from fibrosis [54, 55, 100]. This notion is also supported by the results from different mouse models of kidney diseases induced in mice lacking Smad3 or Smad7 or having conditional knockout (KO) for Smad2 or overexpressing renal Smad7 [54, 55, 62, 74, 98].

In addition, a recent study demonstrates that TGF-β stimulates a crosstalk circuit between p53 and miR-192 related to the pathogenesis of DN [58]. It is known that expression levels of TGF-β1, p53, and miR-192 are increased in expanded glomeruli of diabetic mice [58, 101, 102]. Suppression of miR-192 function in vivo inhibits p53 expression in the renal cortex of control and streptozotocin injected diabetic mice [58]. Results from miR-192 KO type 1 diabetic mice confirm this positive relationship between miR-192 and renal expression of TGF-β and p53 [58]. All these results suggest that the TGF-β/Smad3 signaling plays an essential role of regulating microRNA expression during DN.

### 6. Therapeutic Potential of MicroRNAs in Diabetic Kidney Disease

In addition to the investigation of the role of microRNAs in DN, the recent focus has shifted to determine the therapeutic potential of the microRNAs in diabetic kidney disease. Restoring expression or inhibition of microRNAs in cells under diabetic condition has shown promising results in suppressing the expression of ECM [63, 65, 96]. Furthermore, in vivo delivery of microRNA mimics, inhibitors, or plasmids for overexpressing or knocking down microRNAs in rodent experimental models provides evidences that altering microRNA activity is a possible way to combat diabetic kidney disease. In vivo delivery of antagoniR-21 not only ameliorates creatinine clearance ratio and urine albumin creatinine ratio, but also decreases tissue inhibitor of metalloproteinase 1 (TIMP-1), Col IV and fibronectin proteins in kidney of diabetic mice [65]. Gene transfer of miR-21 knockout plasmids into the diabetic kidneys of db/db mice at age 10 weeks significantly ameliorates both microalbuminuria and renal fibrosis and inflammation at age 20 weeks [63]. Knockdown of miR-29c by a specific antisense oligonucleotide restores Sprouty-1 expression and ameliorates albuminuria and mesangial matrix expansion in the type 2 (db/db) diabetic mice [49]. Inhibition of miR-192 with modified antisense oligonucleotides significantly attenuates proteinuria in mice with diabetic kidney disease and suppresses oxidative stress and the renal fibrosis and hypertrophy [59]. Knockdown of miR-215 with antagoniR-215 restores CTNNBIP expression and inhibits Wnt/β-catenin signaling and expression of α-SMA and fibronectin in the db/db mouse kidney [50]. Overexpression of miR-451 inhibits glomerular MC proliferation in vivo [96]. These successful results from rodent diabetic kidney disease models demonstrate two important aspects. Firstly, altering microRNA activity in diabetic kidneys can hold the progression of diabetic kidney diseases which is not shown in current drug treatment. These promising results from experimental models demonstrate the possibility of applying microRNA therapy in the clinical practice. In addition to the conventional plasmid delivery, recent development of chemical modified oligonucleotides, that are stable in the circulation and can freely enter cells to bind to specific microRNA and silence it [30], provides possible and effective delivery methods to ensure the success of microRNA therapy in renal diseases. However, there are still some obstacles for microRNA therapy. Further attention may focus on the risk of off-target effects of microRNAs, specificity of delivery methods, and nonspecific immune response. Therefore, it is still a long way for clinic application with microRNA-based therapy against diabetic kidney disease.

### 7. MicroRNAs as Potential Biomarkers of Diabetic Kidney Disease

Circulating microRNAs in serum, plasma, and urine have been biomarkers of diseases because they can reflect a response to the pathophysiological stresses [103–106]. Investigation of using circulating microRNAs as biomarkers in diabetic kidney disease is ongoing because the delineation of variations of microRNA levels in the body fluids from patients with diabetic kidney disease may provide an understanding of the progression of the disease.

Recent study shows that, when compared urine microRNAs from type 1 patients with persistent and intermittent microalbuminuria, levels of 27 microRNAs are presented at significantly different levels in different stages of untreated nephropathy [107]. These correlations of microRNAs can be mapped to signaling pathways related to renal fibrosis during diabetic kidney disease [107]. A recent present study of assessment about microRNA expression in urinary exosomes from type 1 diabetic patients with and without incipient diabetic nephropathy demonstrates that miR-130a and miR-145 were enriched, while miR-155 and miR-424 reduced in urinary exosomes from patients with microalbuminuria [108]. Interestingly, the increase of urinary exosomal miR-145 levels in an animal model of early experimental diabetic nephropathy is paralleled by miR-145 overexpression within the glomeruli [108]. Treatment with high glucose in cultured MC also upregulates miR-145 levels in both MCs and MC-derived exosomes, suggesting a correlation between circulating microRNA and its renal expression during DN.

MicroRNAs found in circulation or urine appear to be upregulated or downregulated in the progression of diabetic kidney disease. The early detection of their presence in circulation or urine may assist the prediction of the disease course. In order to employ microRNA in the circulation...
and urine as biomarker for determining the severity of diabetic kidney disease and checking the progress of recovery during treatment, the threshold of detection of microRNAs by various amplification methods should be increased. Establishment of a correlation of patterns of microRNAs that are released into the urine or blood by damaged kidneys and renal specific microRNA expression profiles will be useful in advancing this field by comprehensively determining their relevance in the pathogenesis of diabetic kidney disease.

8. Conclusion and Prospective

Recently, microRNAs have emerged as significant post-transcriptional regulators of gene expression in many human diseases [19, 21, 22, 29, 34]. In renal research, more evidence demonstrate that specific microRNAs alter renal physiology by changing expression patterns, mediating actions of TGF-β on renal fibrosis, affecting normal functions of MC, TEC, and podocyte, and inducing ECM deposition, podocyte dysfunction, and albuminuria during renal diseases [24, 28, 33, 34]. However, how microRNAs exactly mediate the diabetic renal injury is underexplored. In principle, one microRNA is capable of regulating multiple target genes. The more the reports of how microRNAs participate in renal injury are, the more their targets are identified. For example, more than eight direct targets of miR-21 and more than ten targets of miR-29 are found in renal research. It gives us a confusion which is the exact mechanism of how a specific microRNA is involved in diabetic renal disease. Up to date, target prediction programs can only be a guide line for the potential microRNA targets and the overlap between algorithms is only minimal. The real target needs to be validated experimentally. But the report about the relationship among the target genes of a specific microRNA is scarce and it is still an open field for future microRNA research. Hopefully, the rapid development of high-throughput validation and proteomic analysis can help us to identify real microRNA targets and determine the exact mechanism of microRNAs in renal diseases in near future.

As overexpression or knockdown of individual microRNAs in a specific cell have provided very useful data on their role in renal biology and pathobiology, generation of a single microRNA knockout in a whole-animal or tissue-specific manner should provide valuable information to confirm the critical role of microRNAs in renal physiology or pathology. For example, knockout mice of miR-21 and miR-192 have confirmed their pathological role in kidney diseases. Presence of these animal models should extend our understanding of how microRNAs work in vivo.

In addition to development of microRNA therapy and biomarkers, searching the polymorphism of microRNAs may be another important clinic approach to investigate the role of microRNAs in human diseases [109–111].

Finally, microRNAs act as important downstream effectors during diabetic kidney disease. The understanding of the specific role of microRNAs during diabetic kidney disease provides us not only a possible alternative to ameliorate disease progression, but also putative biomarkers for predicting diabetic kidney disease.

Conflict of Interests

The authors declare that there is no conflict of interests between the authors and any mentioned identity in the submitted paper.

Acknowledgments

This work was supported by Grants from Major State Basic Research Development Program of China (973 Program, no. 2012CB517700 to Hui Y. Lan) and National Natural Science Foundation of China (General Program 81170681 to Arthur C. Chung and Key Program 81130012 to Xueqing Yu); the Research Grant Council of Hong Kong (RGC GRF 468711, 46910, CUHK5/CRF/09 to Hui Y. Lan.; GRF 463612, 464100, 763908, and 764109 to Arthur C. Chung); the Focused Investment Scheme A and B and direct Grants from the Chinese University of Hong Kong (2011.1.076, 2012.1.021 to Arthur C. Chung); 2011 Research Grant from Hong Kong Society of Nephrology (6903213 to Arthur C. Chung); and Municipal Science and Technology R&D funding of basic research, Shenzhen (Major Program JC201104220290A to Hui Y. Lan and General Program JC201105201059A to Arthur C. Chung). Project support for national and provincial funding from Shenzhen city (GJHS20120702105523297 to Arthur C. Chung).

References


Submit your manuscripts at http://www.hindawi.com